A Phase II, Randomized, Double-blind, Controlled Safety and Immunogenicity Trial of Typhoid Conjugate Vaccine in Children Under 2 Years of Age in Ouagadougou, Burkina Faso: A Methods Paper

被引:8
|
作者
Laurens, Matthew B. [1 ]
Sirima, Sodiomon B. [2 ]
Rotrosen, Elizabeth T. [1 ,4 ]
Siribie, Mohamadou [2 ]
Tiono, Alfred [2 ]
Ouedraogo, Alphonse [2 ]
Liang, Yuanyuan [3 ]
Jamka, Leslie P. [1 ]
Kotloff, Karen L. [1 ]
Neuzil, Kathleen M. [1 ]
机构
[1] Univ Maryland, Sch Med, Ctr Vaccine Dev & Global Hlth, 685 W Baltimore St Room 480, Baltimore, MD 21201 USA
[2] Grp Rech Act Sante, Ouagadougou, Burkina Faso
[3] Univ Maryland, Sch Med, Dept Epidemiol & Publ Hlth, Baltimore, MD 21201 USA
[4] Boston Univ, Sch Med, Boston, MA 02215 USA
基金
比尔及梅琳达.盖茨基金会;
关键词
child; typhoid-paratyphoid vaccines; Burkina Faso; immunogenicity; conjugate; ACELLULAR PERTUSSIS-VACCINE; ENTERICA SEROVAR TYPHI; SUB-SAHARAN AFRICA; IMMUNE-RESPONSE; SALMONELLA; MULTICENTER;
D O I
10.1093/cid/ciy1104
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The recent Typhoid Fever Surveillance in Africa Program demonstrated an overall adjusted incidence of typhoid fever 2-3 times higher than previous estimates in Africa. Recently, a single-dose typhoid conjugate vaccine that allows infants as young as 6 months old to be vaccinated was prequalified by the World Health Organization (WHO). This Vi-based conjugate vaccine demonstrated robust immunogenicity after 1 dose in infants and children 6 through 23 months of age in India with no safety signal, and is currently being tested for the first time on the African continent in Malawi. The WHO Strategic Advisory Group of Experts recommends studies to evaluate co-administering Vi-typhoid conjugate vaccine (Vi-TCV) with routine childhood vaccines in typhoid-endemic countries. The Burkina Faso immunization schedule includes yellow fever vaccine (YFV) at 9 months and meningococcal A conjugate vaccine (MCV-A) at 15 months, in addition to measles-rubella vaccine at both 9 and 15 months. Co-administration testing of Vi-TCV with these routine vaccinations will provide the data needed to support large-scale uptake of Vi-TCV in sub-Saharan Africa. A randomized, controlled, Phase II trial of Vi-TCV co-administration with the vaccinations routinely given at 9 and 15 months of age is planned in Burkina Faso. The overall aim is to assess the safety and immunogenicity of Vi-TCV when co-administered with YFV at 9 months of age and with MCV-A at 15 months of age. A total of 250 participants (100 infants aged 9-11 months and 150 children aged 15-23 months) will be enrolled. Clinical Trials Registration. NCT03614533. The World Health Organization recently prequalified a single-dose, typhoid conjugate vaccine for children as young as 6 months of age. A randomized, controlled clinical trial will assess the safety and immunogenicity of co-administration with routine childhood vaccines in Burkina Faso.
引用
收藏
页码:S59 / S66
页数:8
相关论文
共 50 条
  • [41] Safety and Immunogenicity of a Vi Polysaccharide-Tetanus Toxoid Conjugate Vaccine (Typbar-TCV) in Healthy Infants, Children, and Adults in Typhoid Endemic Areas: A Multicenter, 2-Cohort, Open-Label, Double-Blind, Randomized Controlled Phase 3 Study
    Mohan, Vadrevu Krishna
    Varanasi, Vineeth
    Singh, Anit
    Pasetti, Marcela F.
    Levine, Myron M.
    Venkatesan, Ramasamy
    Ella, Krishna M.
    CLINICAL INFECTIOUS DISEASES, 2015, 61 (03) : 393 - 402
  • [42] Immunogenicity, Reactogenicity, and Safety of Human Papillomavirus 16/18 AS04-Adjuvanted Vaccine in Japanese Women Interim Analysis of a Phase II, Double-blind, Randomized Controlled Trial at Month 7
    Konno, Ryo
    Dobbelaere, Kurt O.
    Godeaux, Olivier O.
    Tamura, Shinobu
    Yoshikawa, Hiroyuki
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2009, 19 (05) : 905 - 911
  • [43] Immunogenicity and safety of three consecutive lots of a new preservative-free inactivated hepatitis A vaccine (Healive®):: A double-blind, randomized and controlled trial
    Jiang, Wei-Ping
    Chen, Jiang-Ting
    Wang, Xu
    Wang, Ya-Long
    Liu, Yan
    Chen, Wen-Yu
    Xu, Wen-Guo
    Qiu, Yuan-Zheng
    Yin, Wei-Dong
    VACCINE, 2008, 26 (18) : 2297 - 2301
  • [44] Immunogenicity and safety of a recombinant fusion protein vaccine (V-01) against coronavirus disease 2019 in healthy adults: a randomized, double-blind, placebo-controlled, phase II trial
    Shu, Ya-Jun
    He, Jian-Feng
    Pei, Rong-Juan
    He, Peng
    Huang, Zhu-Hang
    Chen, Shao-Min
    Ou, Zhi-Qiang
    Deng, Jing-Long
    Zeng, Pei-Yu
    Zhou, Jian
    Min, Yuan-Qin
    Deng, Fei
    Peng, Hua
    Zhang, Zheng
    Wang, Bo
    Xu, Zhong-Hui
    Guan, Wu-Xiang
    Hu, Zhong-Yu
    Zhang, Ji-Kai
    CHINESE MEDICAL JOURNAL, 2021, 134 (16) : 1967 - 1976
  • [45] Immunogenicity and safety of a recombinant fusion protein vaccine (V-01) against coronavirus disease 2019 in healthy adults: a randomized, double-blind, placebo-controlled, phase II trial
    Shu Ya-Jun
    He Jian-Feng
    Pei Rong-Juan
    He Peng
    Huang Zhu-Hang
    Chen Shao-Min
    Ou Zhi-Qiang
    Deng Jing-Long
    Zeng Pei-Yu
    Zhou Jian
    Min Yuan-Qin
    Deng Fei
    Peng Hua
    Zhang Zheng
    Wang Bo
    Xu Zhong-Hui
    Guan Wu-Xiang
    Hu Zhong-Yu
    Zhang Ji-Kai
    中华医学杂志英文版, 2021, 134 (16) : 1967 - 1976
  • [46] Safety and Immunogenicity of the ID93+GLA-SE Tuberculosis Vaccine in BCG-Vaccinated Healthy Adults: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial
    Choi, Yu Hwa
    Kang, Young Ae
    Park, Kwang Joo
    Choi, Jae Chol
    Cho, Kwan Goo
    Ko, Da Yeon
    Ahn, Jun Ho
    Lee, Boram
    Ahn, Eunsol
    Woo, Yun Ju
    Jung, Kwangsoo
    Kim, Nan Yul
    Reese, Valerie A. A.
    Larsen, Sasha E. E.
    Baldwin, Susan L. L.
    Reed, Steven G. G.
    Coler, Rhea N. N.
    Lee, Hyejon
    Cho, Sang-Nae
    INFECTIOUS DISEASES AND THERAPY, 2023, 12 (06) : 1605 - 1624
  • [47] Efficacy of an 11-Valent Pneumococcal Conjugate Vaccine Against Radiologically Confirmed Pneumonia Among Children Less Than 2 Years of Age in the Philippines A Randomized, Double-Blind, Placebo-Controlled Trial
    Lucero, Marilla G.
    Nohynek, Hanna
    Williams, Gail
    Tallo, Veronica
    Simoes, Eric A. F.
    Lupisan, Socorro
    Sanvictores, Diozele
    Forsyth, Simon
    Puumalainen, Taneli
    Ugpo, Juanita
    Lechago, Marites
    de Campo, Margaret
    Abucejo-Ladesma, Erma
    Sombrero, Lydia
    Nissinen, Antti
    Soininen, Anu
    Ruutu, Petri
    Riley, Ian
    Makela, Helen P.
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2009, 28 (06) : 455 - 462
  • [48] Immunogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccines in participants >/=3 years of age: a double-blind, randomized, parallel-controlled phase III clinical trial in China
    Wang, Shi-Yuan
    Liu, Shu-Zhen
    Chu, Kai
    Zhao, Yue
    Zhu, Feng-Cai
    Hu, Yue-Mei
    Meng, Fan-Yue
    Li, Jing-Xin
    Luo, Li
    Yang, Jia-Ying
    Liu, Pei
    Yu, Jun
    EXPERT REVIEW OF VACCINES, 2017, 16 (11) : 1155 - 1169
  • [49] A Phase 1, double-blind, randomized, placebo-controlled study to evaluate the safety and immunogenicity of a tetravalent live attenuated dengue vaccine in adults
    Gunale, Bhagwat
    Farinola, Nicholas
    Yeolekar, Leena
    Shrivastava, Shubham
    Girgis, Hanna
    Poonawalla, Cyrus S.
    Dhere, Rajeev M.
    Arankalle, Vidya
    Mishra, Akhilesh Chandra
    Mehla, Rajeev
    Kulkarni, Prasad S.
    VACCINE, 2023, 41 (38) : 5614 - 5621
  • [50] Safety and immunogenicity of high doses of quadrivalent influenza vaccine in children 6 months through <18 years of age: A randomized controlled phase II dose-finding trial
    Chang, Lee-Jah
    Anderson, Evan J.
    Jeanfreau, Robert
    He, Ying
    Hicks, Bryony
    Shrestha, Anju
    Pandey, Aseem
    Landolfi, Victoria
    DeBruijn, Iris
    VACCINE, 2021, 39 (11) : 1572 - 1582